Myomo (MYO) Stock Price, News & Analysis

Company Overview

Myomo, Inc. (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America. The company provides training, fitting and ongoing support to clinicians and patients, while also securing reimbursement agreements with Medicare and private insurers. In addition to its core device offering, Myomo continues to invest in software enhancements and data analytics to improve patient outcomes and support clinician decision-making.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Myomo emerged from research conducted at the Massachusetts Institute of Technology. Since its inception, the company has focused on translating advanced robotics technology into practical medical solutions. Myomo completed its initial public offering in 2014, enabling expanded clinical trials and commercialization efforts.

Looking ahead, Myomo is pursuing next-generation wearable orthoses that aim to reduce device weight, enhance battery life and broaden indications to other parts of the body. The company’s ongoing research and development efforts remain centered on improving quality of life for patients with neuromuscular impairments and advancing the field of medical robotics.

Key Stats

• Today's Range: $0.96 to $1.10
• 50-Day Range: $0.64 to $1.04
• 52-Week Range: $0.61 to $3.22
• Volume: 1.53 million shs
• Average Volume: 373,319 shs
• Market Capitalization: $40.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.67
• Consensus Rating: Buy

Myomo Stock Analysis - MarketRank™

Myomo scored higher than 77% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Myomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Myomo has a consensus price target of $7.67, representing about 637.2% upside from its current price of $1.04.

Amount of Analyst Coverage

Myomo has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Myomo are expected to grow in the coming year, from ($0.28) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myomo is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myomo is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myomo has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.41% of the float of Myomo has been sold short.

Short Interest Ratio / Days to Cover

Myomo has a short interest ratio ("days to cover") of 13.06, which indicates bearish sentiment.

Change versus previous month

Short interest in Myomo has recently decreased by 1.29%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myomo does not currently pay a dividend.

Dividend Growth

Myomo does not have a long track record of dividend growth.

News and Social Media

• Score: 4.7 / 5
• News Sentiment: 1.45

News Sentiment

Myomo has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Myomo this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for MYO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

8 people have added Myomo to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Myomo in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $358,416.00 in company stock, which represents 0.8919% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Myomo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $358,416.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

4.79% of the stock of Myomo is held by insiders.

Percentage Held by Institutions

44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2025
• Today: 5/23/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:MYO
• CIK: 1369290
• Web: myomo.com
• Phone: (617) 996-9058
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Myomo: $7.67
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +637.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.57 million
• Net Margins: -36.69%
• Pretax Margin: -35.34%
• Return on Equity: -119.60%
• Return on Assets: -42.50%

Debt

• Debt-to-Equity Ratio: 1.21
• Current Ratio: 2.73
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: $40.93 million
• Price / Sales: 0.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.23 per share
• Price / Book: 4.52

Miscellaneous

• Outstanding Shares: 38,640,000
• Free Float: 36,788,000
• Market Cap: $40.19 million
• Optionable: Not Optionable
• Beta: 1.39